Impact of Medicare prescription drug (Part D) coverage expansion on utilisation and financial burden of benzodiazepines among older adults: an interrupted time series analysis

ObjectiveBenzodiazepines were excluded from Medicare Part D coverage since its introduction in 2006. Part D expanded coverage for benzodiazepines in 2013. The objective was to examine the impact of Medicare Part D coverage expansion on the utilisation and financial burden of benzodiazepines in older adults.DesignInterrupted time series with a control group.SettingNationally representative sample.Participants53 150 468 users of benzodiazepines and 21 749 749 users of non-benzodiazepines (an alternative therapy) from the Medicare Current Beneficiary Survey between the pre-expansion (2006–2012) and post-expansion (2013–2017) periods.InterventionMedicare Part D coverage expansion on benzodiazepines.Primary and secondary outcome measuresAnnual rate of benzodiazepines and non-benzodiazepines, average number of benzodiazepines and non-benzodiazepines and average cost of benzodiazepines and non-benzodiazepines.ResultsAfter Medicare Part D coverage expansion, the level of the annual rate of benzodiazepines increased by 8.20% (95% CI: 6.07% to 10.32%) and the trend decreased by 1.03% each year (95% CI: −1.77% to −0.29%). The trend of the annual rate of non-benzodiazepines decreased by 0.72% each year (95% CI: −1.11% to −0.33%). For the average number of benzodiazepines, the level increased by 0.67 (95% CI: 0.52 to 0.82) and the trend decreased by 0.10 each year (95% CI: −0.15 to –0.05). For the average number of non-benzodiazepines, the level decreased by 0.11 (95% CI: −0.21 to –0.01) and the trend decreased by 0.04 each year (95% CI: −0.08 to –0.01). No significant level and trend changes were identified for the average cost of benzodiazepines and non-benzodiazepines.ConclusionsAfter Medicare Part D coverage expansion, there was a sudden increase in the utilisation of benzodiazepines and a decreasing trend in the long-term. The increase in the utilisation of benzodiazepines did not add a financial burden to older adults. As an alternative therapy, the utilisation of non-benzodiazepines decreased following the coverage expansion.

The Electoral Consequences of Cellphone Coverage Expansion

We study the electoral effects of cellphone coverage expansion in Ghana between 2004 and 2008 using a difference-in-differences design and find that it benefits incumbents in both presidential and parliamentary elections, with gains in the latter concentrated among incumbents from the ruling party. This appears to be due to cellphone coverage expansion improving citizens' wealth and faith in the economy as opposed to their perceptions of government performance or political knowledge.

Health Care Crisis Unabated: A Review of Recent Data on Health Care in the United States

We review recently published studies of U.S. health policy and the nation’s health care system. Even prior to the COVID-19 pandemic, health inequalities were widening and care was inequitably distributed. Although the Affordable Care Act’s coverage expansion improved access to care and timely cancer diagnoses, a large proportion of U.S. residents continued to avoid medical care due to concerns about costs, and access to mental health services remains particularly inadequate. Yet more evidence of private insurers’ profit-driven misbehaviors and of corruption among medical leaders continues to emerge. Misguided incentives and lax regulation encourages nominally nonprofit health care providers to mimic for-profits’ misconduct, and rapacious investors own and control an increasing share of physicians’ practices. Pharmaceutical firms wield outsize political influence and devote far more funds to rewarding investors than to research and development effort. Yet despite vigorous efforts by pharma and other commercial interests to denigrate national health insurance, polls indicate that the COVID-19 pandemic has led to increasing support for such reform.